Aims To evaluate the pupillary effects of single doses of the a 2 -adrenoceptor agonist clonidine and the a 2 -adrenoceptor antagonist yohimbine under several illumination conditions. Methods Sixteen healthy male volunteers received clonidine 0.2 mg, yohimbine 22 mg, clonidine 0.2 mg+ yohimbine 22 mg in a double-blind placebo-controlled, cross-over study. 2 h post drug ingestion pupil diameter was recorded in darkness, and at luminance levels of 6 Cd m x2 , 91 Cd m x2 and 360 Cd m x2 . The effects of the active treatments on pupil diameter were also expressed as the differences from the placebo condition (`placebo-corrected' data; mean [95% CI]). Results Clonidine had little effect on pupil diameter in darkness; however, it caused a signi®cant, light-dependent, miosis when the eye was illuminated. On the other hand yohimbine increased pupil size; this increase was signi®cant at 91 and 360 Cd m x2 . There were no signi®cant differences between the effects of the combined treatment (clonidine 0.2 mg+ yohimbine 22 mg) and the effect of placebo. Conclusions The pupillary effects of clonidine and yohimbine are likely to re¯ect the interaction of these drugs with inhibitory a 2 -adrenoceptors located on central noradrenergic neurones, which in turn would lead to a decrease and an increase, respectively, in sympathetic out¯ow to the iris. The light dependence of the pupillary effects of these drugs, however, suggests that the parasympathetic light re¯ex pathway is also involved, which is known to be under inhibitory control from the central noradrenergic neurones. Modulation of parasympathetic out¯ow seems to play an important role since both drugs had relatively little effect on pupil diameter in darkness when sympathetic activity predominates.